Stock Price Quote

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE1547.05-46.6 (-2.92 %)
PREV CLOSE ( ) 1593.65
OPEN PRICE ( ) 1579.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 50239
TODAY'S LOW / HIGH ( )1541.05 1581.35
52 WK LOW / HIGH ( )678.9 1703.8
NSE1547.55-46.5 (-2.92 %)
PREV CLOSE( ) 1594.05
OPEN PRICE ( ) 1575.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1547.55 (167)
VOLUME 1186398
TODAY'S LOW / HIGH( ) 1541.00 1584.00
52 WK LOW / HIGH ( )678.55 1704.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1983
Management Info
Manju D Gupta - Chairman Nilesh Gupta - Managing Director
Registered Office

Address Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone 022 66402323

Email info@lupin.com

Website www.lupin.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

18Apr Announcement under Regulation 30 (LOD
Intimation regarding allotment of 59809 shares under ESOP.
15Apr Lupin informs about stop transfer
Lupin has informed that it enclosed the details of share certificate, re..
12Apr USFDA completes GMP inspection at Lupi
United States Food and Drug Administration (USFDA) has completed a GMP I..
12Apr Lupin informs about press release
Lupin has informed that it enclosed a Press Release as regards, the succ..
10Apr Lupin, Lemon Tree Hotels and Exide Ind
Lupin has launched first generic version of Oracea (Doxycycline Capsules..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit9164.399999999994252.10000000001
Gross Profit 10839.6 5271.40000000001
Operating Profit 1240511739.2
Net Sales 41157.5112588.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

NON-INSTITUTION 6.93%
PROMOTERS 47.01%
MUTUAL FUNDS/UTI 16.82%
FI/BANKS/INSURANCE 10.02%
GOVERNMENT 0.01%
FII 0%

About Lupin Ltd.

Lupin Ltd. was incorporated in the year 1983. Its today's share price is 1547.05. Its current market capitalisation stands at Rs 70506.82 Cr. In the latest quarter, company has reported Gross Sales of Rs. 113193.3 Cr and Total Income of Rs.114688.5 Cr. The company's management includes R V Satam, Mark D McDade, Punita Kumar Sinha, K B S Anand, Jean-Luc Belingard, Ramesh Swaminathan, Nilesh Gupta, Vinita Gupta, Manju D Gupta.

It is listed on the BSE with a BSE Code of 500257 , NSE with an NSE Symbol of LUPIN and ISIN of INE326A01037. It's Registered office is at Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East)Mumbai-400055, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arora & Arora, BSR & Co LLP, Deloitte Haskins & Sells, Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SS Kapoor & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.